Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination

Cancer Gene Therapy

Volumn 8, Issue 8, 2001, Pages 599-611

  Weth, Robert ^a   Christ, Oliver ^a   Stevanovic, Stefan ^b   Zöller, Margot ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Institute for Cell Biology   (Germany)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

B16 melanoma; Dendritic cells; gp100; Invariant chain; Salmonella

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN GP 100; H2 ANTIGEN; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE TARGETING; HELPER CELL; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; VACCINATION;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DNA PRIMERS; GENE TRANSFER TECHNIQUES; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

ANIMALIA; MURINAE; SALMONELLA; SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 0034861450     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700352     Document Type: Article

References (85)

1. Tumor antigens recognized by T lymphocytes
2. Immunology and immunotherapy of human cancer: Present concepts and clinical developments
3. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100
4. Analysis of Pme117/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and genetherapy
5. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
6. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy
7. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
8. New cancer therapy by immunomanipulation: Development of immunotherapy for human melanomas as a model system
9. New treatment options for patients with melanoma: Review of melanoma-derived T cell epitope-based peptide vaccines
10. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
11. Experimental vaccine strategies for cancer immunotherapy
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector encoding endogenous tumor-associated antigens
14. Murine dendritic cells transfected with human gp100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating antitumor immunity
15. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
16. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
17. Gp100/pme117 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
18. Cloning and characterization of the genes encoding the murine homologues of the human antigens MART1 and gp100
19. An autologous oral DNA vaccine protects against murine melanoma
20. Vaccination against human cancer
21. Adoptive cellular therapy
22. Dendritic cell vaccines for cancer immunotherapy
23. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy
24. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
25. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
26. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen-pulsed dendritic cells
27. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
28. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
29. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
30. Rejection of mouse sarcoma after transfection of MHC class II genes
31. Help for cytotoxic T cell responses is mediated by CD40 signalling
32. The central role of CD4(+) T cells in the antitumor immune response
33. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
34. + cytotoxic T lymphocyte activation in mice
35. + lymphocytes in the initiation of class I restricted reactivity to a tumor/self peptide
36. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response
37. Induction of TH1 and TH2 responses: A key role for the "natural" immune response?
38. Immunotherapy of cancer with dendritic cell-based vaccines
39. RNA melanoma vaccine: Induction of antitumor immunity by human glycoprotein 100 mRNA immunization
40. DNA- and RNA-based vaccines: Principles, progress and prospects
41. DNA vaccines: Basic mechanism and immune responses
42. DNA vaccines: Protective immunization by parenteral mucosal and gene-gun inoculations
43. Current challenges in cancer gene therapy
44. Control of immune responses by gene immunization
45. Immunostimulatory CpG oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
46. Live attenuated Salmonella: A paradigm of mucosal vaccines
47. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine
48. Salmonella vaccine carrier strains: Effective delivery system to trigger antitumor immunity by oral route
49. Oral somatic transgene vaccination using attenuated S. typhimurium
50. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma
51. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment
52. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
53. MHC class II-associated invariant chain peptide replacement by T cell epitopes: Engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation
54. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells
55. Biological behavior of malignant melanoma cells correlated to their survival in vivo
56. Alloreactive cytolytic T cell clones preferentially recognize conformational determinants on histocompatibility antigens: Analysis with genetically engineered hybrid antigens
57. Cross-blocking studies with monoclonal antibodies against I-A molecules of haplotypes b, d and k
58. Aromatic-dependent Salmonella typhimurium are nonvirulent and effective as live vaccines
59. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
60. SYFPEITHI: Database for MHC ligands and peptide motifs
61. The JAM test. A simple assay for DNA fragmentation and cell death
62. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective antimelanoma immunity
63. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
64. CIIV, MIIC and other compartments for MHC class II loading
65. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
66. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
67. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
68. + T cells
69. In vitro and in vivo induction of a Th cell response towards peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program
70. Recombinant gp100 protein presented by dendritic cells elicits a T-helper response in vitro and in vivo
71. Comparative evaluation of DNA versus protein vaccination in tumor therapy
72. Cells and cytokines in immunotherapy and gene therapy of cancer
73. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
74. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
75. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium
76. Dendritic cells in genetic immunization
77. Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors
78. Antibody-IL-2 fusion proteins: A novel strategy for immune protection
79. Efficacy of local versus systemic application of antibody cytokine fusion proteins in tumor therapy
80. IL2- and TNF-antibody fusion proteins induce different antitumor immune responses in vivo
81. Immune selection after antigen-specific immunotherapy of melanoma
82. + cytotoxic T cell responses: Evidence for immunoselection of antigen loss variants in vivo
83. Tumor escape from immune recognition: Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6
84. The role of CTLA-4 in the regulation of T cell immune responses